Home Endocrinology & Hormones Glucocorticoid Receptor agonist Fluticasone propionate

research use only

Fluticasone propionate Glucocorticoid Receptor agonist

Cat.No.S1992

Fluticasone Propionate (CCI-187881) is a synthetic glucocorticoid, used to treat non-allergic and allergic rhinitis.
Fluticasone propionate Glucocorticoid Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 500.57

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S199201 DMSO]100 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 99.97%
99.97

Chemical Information, Storage & Stability

Molecular Weight 500.57 Formula

C25H31F3O5S

 Storage (From the date of receipt)
CAS No. 80474-14-2 Download SDF Storage of Stock Solutions

Synonyms CCI-187881 Smiles CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (199.77 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Glucocorticoid receptor [1]
In vitro
Fluticasone propionate (1 pM) inhibits the constitutive and TGF-beta-induced expression of alpha-SMA in human lung myofibroblasts. This compound blocks the TNF-alpha-induced nuclear translocation of the pro-inflammatory transcription factor NF-kappaB in human lung myofibroblasts. [1] It inhibits in lung myofibroblasts, at a very early stage of differentiation, the activation of Janus kinase/STAT pathways induced by IL-13 (tyrosine kinase 2, STAT1, STAT3, STAT6, mitogen-activated protein kinase). This chemical still displays a potential anti-inflammatory activity even if it only inhibits tyrosine kinase 2 phosphorylation in mildly or fully differentiated myofibroblastic cultures. It inhibits constitutive and TGF-beta-induced expression of alpha-smooth muscle actin, the main marker of myofibroblastic differentiation, both in very early and in mild differentiated myofibroblasts. This compound displays an additional powerful anti-inflammatory effect, decreasing nuclear translocation of NF-kappaB independent of the degree of myofibroblastic differentiation. [2] It inhibits allergen-induced T-cell proliferation, expression of IL-3, IL-5 and GM-CSF mRNA, and secretion of the corresponding proteins in a concentration-dependent fashion. This chemical has the potential markedly to inhibit allergen-induced T-cell production of asthma-relevant cytokines. [3]
In vivo
Fluticasone propionate administrated after induction of a severe heaves exacerbation results in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in bronchoalveolar lavage (BAL) neutrophilia in horse. [4]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06290102 Recruiting
Asthma
Teva Branded Pharmaceutical Products R&D Inc.
 May 2 2024 Phase 1
NCT02630121 Recruiting
Sleep Apnea|Chronic Nasal Congestion
University of South Florida
 April 2023 Phase 4
NCT05608681 Recruiting
Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc.
 March 31 2023 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.